EUVIMEDEUVIMED entdecken
Crossref

Model-based evaluation of adherence to bedaquiline and clofazimine in adults with drug-resistant TB

J E Resendiz-Galvan, R A Murphy, T Govender, G A K Teponnou, L Wiesner, R Court, S G Louis, G Maartens, P Denti

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.24.0610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von J E Resendiz-Galvan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa. Hauptthemen laut MEDLINE: Diarylquinolines, Tuberculosis, Multidrug-Resistant, Clofazimine, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

There is a need for objective measures of adherence to fully-oral bedaquiline-based regimens for rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB). Due to their prolonged half-lives, bedaquiline (BDQ) and clofazimine CFZ) are appropriate for evaluating long-term treatment adherence using a model-based approach.





METHODS

We enrolled adults initiating a 9-month regimen that included BDQ and CFZ for RR/MDR-TB. Dried blood spot samples were taken at intervals and assayed for BDQ and CFZ concentrations. Demographic and clinical factors were used to predict drug concentrations using known pharmacokinetic models, assuming full adherence. Individual observed concentrations were compared to model-predicted values (1000 simulations). Observations were ranked, with those below the 5 th percentile of simulated concentrations, indicating possible poor adherence.





RESULTS

Adherence worsened over time, especially for BDQ (11, 21, 26, and 35% of the observations below the 5 th percentile in the first, second, fourth, and sixth month respectively). CFZ observations under the 5 th percentile were 10, 9, 7.5, 14, and 23% at months 1, 2, 4, 6, and 9.





CONCLUSION

Concentrations of BDQ and CFZ below the 5 th percentile increased over time and this trend was more marked with BDQ. We hypothesise that the complexity of the thrice-weekly BDQ regimen increases the risk of suboptimal adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiarylquinolinesTuberculosis, Multidrug-ResistantClofazimineAntitubercular AgentsHumansAdultMaleFemaleMiddle AgedMedication AdherenceYoung AdultHalf-LifeAgedDrug Therapy, CombinationRifampin

Substanzen

bedaquilineDiarylquinolinesClofazimineAntitubercular AgentsRifampin

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
  • Geisel School of Medicine at Dartmouth, NH, USA;, White River Junction Veterans Affairs Medical Center, VT, USA.
  • King Dinizulu Hospital Center, Durban, South Africa.
  • University of Southern California, CA, USA.

Zitieren

APA

Resendiz-Galvan, J. E., Murphy, R. A., Govender, T., Teponnou, G. A. K., Wiesner, L., Court, R., Louis, S. G., Maartens, G., & Denti, P. (2025). Model-based evaluation of adherence to bedaquiline and clofazimine in adults with drug-resistant TB. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0610

Vancouver

Resendiz-Galvan JE, Murphy RA, Govender T, Teponnou GAK, Wiesner L, Court R, et al. Model-based evaluation of adherence to bedaquiline and clofazimine in adults with drug-resistant TB. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.24.0610

BibTeX
@article{ResendizGalvan2025,
  author = {Resendiz-Galvan, J E and Murphy, R A and Govender, T and Teponnou, G A K and Wiesner, L and Court, R and Louis, S G and Maartens, G and Denti, P},
  title = {Model-based evaluation of adherence to bedaquiline and clofazimine in adults with drug-resistant TB},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.24.0610}
}
Kostenlos starten →